廣告
香港股市 已收市
  • 恒指

    18,028.52
    -306.80 (-1.67%)
     
  • 國指

    6,439.82
    -116.28 (-1.77%)
     
  • 上證綜指

    2,998.14
    -7.30 (-0.24%)
     
  • 滬深300

    3,495.62
    -7.66 (-0.22%)
     
  • 美元

    7.8052
    +0.0004 (+0.01%)
     
  • 人民幣

    0.9297
    -0.0001 (-0.01%)
     
  • 道指

    39,150.33
    +15.57 (+0.04%)
     
  • 標普 500

    5,464.62
    -8.55 (-0.16%)
     
  • 納指

    17,689.36
    -32.23 (-0.18%)
     
  • 日圓

    0.0487
    -0.0002 (-0.41%)
     
  • 歐元

    8.3466
    -0.0079 (-0.09%)
     
  • 英鎊

    9.8720
    -0.0060 (-0.06%)
     
  • 紐約期油

    80.63
    -0.66 (-0.81%)
     
  • 金價

    2,335.40
    -33.60 (-1.42%)
     
  • Bitcoin

    64,250.01
    -788.26 (-1.21%)
     
  • CMC Crypto 200

    1,329.94
    -30.39 (-2.24%)
     

EverQuote (EVER) Surges 89.6% YTD: Will the Rally Last?

EverQuote, Inc.’s EVER shares have rallied 89.6% year to date (YTD) compared with the industry's growth of 7.9%. The Finance sector and the Zacks S&P 500 composite have risen 4% and 11.3%, respectively, in the same time frame. With a market capitalization of $805.62 million, the average volume of shares traded in the last three months was 0.48 million.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The rally was largely driven by increasing consumer traffic, higher quote request volume, solid performance of automotive and other insurance marketplace verticals and favorable growth estimates.

This multi-line insurer carries a Zacks Rank #2 (Buy) at present. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.16%.

Will the Bull Run Continue?

The Zacks Consensus Estimate for EverQuote’s 2024 earnings per share indicates a year-over-year increase of 102.6%. The consensus estimate for revenues is pegged at $385.39 million, implying a year-over-year improvement of 33.8%.

The consensus estimate for 2025 earnings per share and revenues indicates an increase of 362.50% and 21.09%, respectively, from the corresponding 2024 estimates.

EVER has a VGM Score of B. VGM Score helps identify stocks with the most attractive value, best growth and the most promising momentum.

Back-tested results show that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2 offer the best opportunities in the value investing space.

EverQuote’s top line has been increasing over the years owing to the solid performance of automotive and other insurance marketplace verticals. It remains well-poised to gain from the normalization of auto insurance carrier demand, given auto carrier recovery. It also remains focused on rapidly expanding into new verticals.

Increasing consumer traffic, higher quote request volume and innovating advertiser products and services will continue to drive revenues. EverQuote expects revenues between $100 million and $105 million in the second quarter of 2024.

The variable marketing margin (VMM) is likely to gain from declining customer acquisition costs and a shift in the revenue mix to local agent networks with higher VMMs. EVER expects the dynamics of the auto insurance market to put pressure on VMM within the auto insurance vertical. Apart from the auto insurance vertical, the company expects VMM to benefit from strong revenue growth within the health direct-to-consumer agency during the annual health open enrollment period. This is expected to drive an improvement in the VMM operating point for the business. The insurer expects VMM in the second quarter of 2024 between $31 million and $33 million.

EVER boasts a debt free balance sheet with cash balance improving over the last three years. The company aims to meet any future debt service obligations with the existing cash and cash equivalents and cash flows from operations, which are expected to be sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months, without considering liquidity available from the revolving line of credit.

In its efforts to strengthen its balance sheet and liquidity position, EverQuote modified its existing loan agreement with Western Alliance Bank. The company has a $25 million undrawn working capital line of credit with Western Alliance Bank, which is available until July 2025.

EVER also has an impressive Growth Score of B. This style score helps analyze the growth prospects of a company.

Other Stocks to Consider

Some other top-ranked stocks from the multi-line insurance industry are Lemonade, Inc. LMND, Old Republic International Corporation ORI and Radian Group Inc. RDN, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
   
Lemonade has a solid track record of beating earnings estimates in each of the trailing four quarters, the average being 12.82%. Shares of LMND have inched up 0.8% YTD.

The Zacks Consensus Estimate for LMND’s 2024 and 2025 earnings implies year-over-year growth of 13.5% and 18.3%, respectively.

Old Republic International has a solid track record of beating earnings estimates in three of the trailing four quarters and missing in one, the average being 6.61%. Shares of ORI have gained 4.9% YTD.

The Zacks Consensus Estimate for ORI’s 2024 and 2025 earnings implies year-over-year growth of 3.8% and 4.4%, respectively.

Radian has a solid track record of beating earnings estimates in each of the trailing four quarters, the average being 22.79%. Shares of RDN have climbed 9.6% YTD.

The Zacks Consensus Estimate for RDN’s 2024 and 2025 revenues implies year-over-year growth of 8.2% and 4.9%, respectively.

廣告

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Radian Group Inc. (RDN) : Free Stock Analysis Report

EverQuote, Inc. (EVER) : Free Stock Analysis Report

Old Republic International Corporation (ORI) : Free Stock Analysis Report

Lemonade, Inc. (LMND) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research